» Articles » PMID: 37047596

Quantitative Susceptibility Mapping and Amide Proton Transfer-Chemical Exchange Saturation Transfer for the Evaluation of Intracerebral Hemorrhage Model

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2023 Apr 13
PMID 37047596
Authors
Affiliations
Soon will be listed here.
Abstract

This study aimed to evaluate an intracerebral hemorrhage (ICH) model using quantitative susceptibility mapping (QSM) and chemical exchange saturation transfer (CEST) with preclinical 7T-magnetic resonance imaging (MRI) and determine the potential of amide proton transfer-CEST (APT-CEST) for use as a biomarker for the early detection of ICH. Six Wistar male rats underwent MRI, and another six underwent histopathological examinations on postoperative days 0, 3, and 7. The ICH model was created by injecting bacterial collagenase into the right hemisphere of the brain. QSM and APT-CEST MRI were performed using horizontal 7T-MRI. Histological studies were performed to observe ICH and detect iron deposition at the ICH site. T-weighted images (TWI) revealed signal changes associated with hemoglobin degeneration in red blood cells, indicating acute-phase hemorrhage on day 0, late-subacute-phase hemorrhage on day 3, and chronic-phase hemorrhage on day 7. The susceptibility alterations in each phase were detected using QSM. QSM and Berlin blue staining revealed hemosiderin deposition in the chronic phase. APT-CEST revealed high magnetization transfer ratios in the acute phase. Abundant mobile proteins and peptides were observed in early ICH, which were subsequently diluted. APT-CEST imaging may be a reliable noninvasive biomarker for the early diagnosis of ICH.

Citing Articles

The Effect of Acupuncture on Brain Iron Deposition and Body Iron Metabolism in Vascular Cognitive Impairment: Protocol for a Randomized Controlled Trial.

Wu M, Chen L, Wang Y, Li Y, An Y, Wu R JMIR Res Protoc. 2024; 13:e56484.

PMID: 38885500 PMC: 11217710. DOI: 10.2196/56484.


Post-Surgical Depositions of Blood Products Are No Major Confounder for the Diagnostic and Prognostic Performance of CEST MRI in Patients with Glioma.

von Knebel Doeberitz N, Kroh F, Konig L, Boyd P, Grass S, Bauspiess C Biomedicines. 2023; 11(9).

PMID: 37760790 PMC: 10525358. DOI: 10.3390/biomedicines11092348.

References
1.
Liu C, Li W, Tong K, Yeom K, Kuzminski S . Susceptibility-weighted imaging and quantitative susceptibility mapping in the brain. J Magn Reson Imaging. 2014; 42(1):23-41. PMC: 4406874. DOI: 10.1002/jmri.24768. View

2.
Tanoue M, Saito S, Takahashi Y, Araki R, Hashido T, Kioka H . Amide proton transfer imaging of glioblastoma, neuroblastoma, and breast cancer cells on a 11.7 T magnetic resonance imaging system. Magn Reson Imaging. 2019; 62:181-190. DOI: 10.1016/j.mri.2019.07.005. View

3.
Weerink L, Appelman A, Kloet R, van der Hoorn A . Susceptibility-weighted imaging in intracranial hemorrhage: not all bleeds are black. Br J Radiol. 2022; 96(1148):20220304. PMC: 10392652. DOI: 10.1259/bjr.20220304. View

4.
Rerich E, Zaiss M, Korzowski A, Ladd M, Bachert P . Relaxation-compensated CEST-MRI at 7 T for mapping of creatine content and pH--preliminary application in human muscle tissue in vivo. NMR Biomed. 2015; 28(11):1402-12. DOI: 10.1002/nbm.3367. View

5.
Onishi R, Sawaya R, Tsuji K, Arihara N, Ohki A, Ueda J . Evaluation of Temozolomide Treatment for Glioblastoma Using Amide Proton Transfer Imaging and Diffusion MRI. Cancers (Basel). 2022; 14(8). PMC: 9031574. DOI: 10.3390/cancers14081907. View